The following is a list of publications co-authored by GSID researchers and our colleagues. For complete citations, please download a print version here. |
| Authors - Short | Title | Publication | Year | Field | GSID Author(s) |
|---|---|---|---|---|---|
| Shubin et al | Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability | AIDS. 2023 Aug 1;37(10):1519-1524 | 2023 | HIV | Faruk Sinangil |
| Costanzo et al | ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone | JCI Insight. 2023;8(9):e167664 | 2023 | HIV | Faruk Sinangil |
| Sironi et al | No association of a risk variant for severe COVID-19 with HIV protection in three cohorts of highly exposed individuals | PNAS Nexus, 2022, 1, 1–4 | 2022 | HIV, COVID-19 | Faruk Sinangil |
| Meza et al | IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men | Virulence, 2022 Dec;13(1):757-763 | 2022 | HIV | Faruk Sinangil |
| Huang et al | AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period | Vaccine,Volume 39, Issue 33, 30 July 2021, Pages 4641-4650 , doi.org/10.1016/j.vaccine.2021.06.066 | 2021 | HIV | Carter Lee, Vineeta Gulati, Faruk Sinangil |
| Pitisuttithum et al | Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. | Lancet HIV. 2020 Feb 6. pii: S2352-3018(19)30406-0. doi: 10.1016/S2352-3018(19)30406-0. | 2020 | HIV | Faruk Sinangil |
| Easterhoff et al | Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. | J Virol. 2020 Jan 31;94(4). pii: e01120-19. doi: 10.1128/JVI.01120-19. | 2020 | HIV | Faruk Sinangil |
| Easterhoff et al | HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. | JCI Insight. 2020 Jan 30;5(2). pii: 131437. doi: 10.1172/jci.insight.131437. | 2020 | HIV | Faruk Sinangil |
| Meza et al | Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine. | AIDS. 2020 Jan 1;34(1):25-32. doi: 10.1097/QAD.0000000000002401 | 2020 | HIV | Faruk Sinangil, Keith Higgins |
| Rouphael et al | DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. | J Clin Invest. 2019 Nov 1;129(11):4769-4785. doi: 10.1172/JCI128699 | 2019 | HIV | Faruk Sinangil |
| Pantaleo et al | Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial | The Lancet HIV. 2019; 6(11): PE737-E749. doi: 10.1016/S2352-3018(19)30262-0 | 2019 | HIV | Carter Lee |
| Gray et al | Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. | Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880. | 2019 | HIV | Faruk Sinangil, Carter Lee |
| Mesa et al | Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens. | PLoS One. 2019 Apr 10;14(4):e0213409. doi: 10.1371/journal.pone.0213409. eCollection 2019 | 2019 | HIV | Faruk Sinangil |
| Akapirat et al | Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. | PLoS One. 2018 Apr 27;13(4):e0196397. doi: 10.1371/journal.pone.0196397. eCollection 2018. | 2018 | HIV | Faruk Sinangil |
| Balasubramanian et al | Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. | Sci Rep. 2018 Jan 11;8(1):542. doi: 10.1038/s41598-017-18863-0. | 2018 | HIV | Faruk Sinangil, Keith Higgins |
| Gilbert et al | Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women | PLOS ONE 12(5): e0176428. https://doi.org/10.1371/journal.pone.0176428 | 2017 | HIV | Don Francis, Carter Lee, and Faruk Sinangil |
| Rerks-Ngarm et al | Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial | J Infect Dis. 2017 Feb 21. doi: 10.1093/infdis/jix099. | 2017 | HIV | Faruk Sinangil |
| Balasubramanian et al | Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination | Vaccine. 2017 Feb 6. pii: S0264-410X(17)30089-0. doi: 10.1016/j.vaccine.2016.11.107. | 2017 | HIV | Faruk Sinangil, Keith Higgins |
| Easterhoff et al | Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial | PLoS Pathog 13(2): e1006182. doi:10.1371/journal.ppat.1006182 | 2017 | HIV | Faruk Sinangil |
| Karnasuta et al | Comparison of Antibody Responses Induced by RV144, VAX003 and VAX004 Vaccination Regimens. | 2017 | HIV | Faruk Sinangil, Don Francis | |
| Luo et al | Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. | JCI Insight. 2016 Dec 8;1(20):e88522. DOI: 10.1172/jci.insight.88522 | 2016 | HIV | Faruk Sinangil, Don Francis, Carter Lee |
| Mahan et al | Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination | PLoS Pathog 12(3): e1005456. doi: 10.1371/journal.ppat.1005456 | 2016 | HIV | Don Francis |
| Karasavvas et al | IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. | AIDS Research and Human Retroviruses. 2015;31(11):1178-1186. doi:10.1089/aid.2015.0034. | 2015 | HIV | Faruk Sinangil, Don Francis |
| Wiehe et al | Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. | Immunity. 2014;41(6):909-918. doi:10.1016/j.immuni.2014.11.014. | 2014 | HIV | Faruk Sinangil |
| Dell et al | Field evaluation of a camera-based mobile health system in low-resource settings. | In Proceedings of the 16th international conference on Human-computer interaction with mobile devices & services (MobileHCI '14). ACM, New York, NY, USA, 33-42. DOI=10.1145/2628363.2628366 | 2014 | mHealth | Ian Francis |
| Chung et al | Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines | Sci Transl Med 19 March 2014: ( 6/ 228: 228-38) Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007736 |
2014 | HIV | Don Francis |
| Arita et al | Variola Viruses | Chapter 21 in Manual of Security Sensitive Microbes and Toxins, Ed. Don Liu. CRC Press 2014. | 2014 | Smallpox | Don Francis |
| Arita et al | Is it time to destroy the smallpox virus? | Science 29 August 2014: 1010. DOI:10.1126/science.345.6200.1010-a | 2014 | Smallpox | Don Francis |
| Francis et al | Global Vaccine Supply - the increasing role of manufacturers from middle income countries | Vaccine 32: 5259-5265; 2014 | 2014 | General | Don Francis |
| Penezina et al | Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants | Clin Vaccine Immunol March 2014 vol. 21 no. 3 391-398 | 2014 | HIV | Keith Higgins |
| Yates et al | Vaccine-Induced Env V1/V2 IgG3 Correlate with Lower HIV-Infection Risk and Declines Soon After Vaccination | Sci Transl Med 19 March 2014: Vol. 6, Issue 228, p. 228ra39 Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007730 |
2014 | HIV | Don Francis, Carter Lee, and Faruk Sinangil |
| Dubin et al | Closing the circle: a thirty-year retrospective on the AIDS/blood epidemic. | Transfusion, 2013, Vol 53 (9), DOI: 10.1111/trf.12374 | 2013 | HIV | Don Francis |
| Gottardo et al | Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial | PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013. | 2013 | HIV | Don Francis, Carter Lee, and Faruk Sinangil |
| Alam et al | Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. | J Virol. 2013 Feb;87(3):1554-68. doi: 10.1128/JVI.00718-12. Epub 2012 Nov 21. | 2013 | HIV | Faruk Sinangil |
| Liao et al | Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | Immunity - 24 January 2013 (Vol. 38, Issue 1, pp. 176-186). doi: 10.1016/j.immuni.2012.11.011 | 2013 | HIV | Faruk Sinangil |
| O'Rourke et al | Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. | J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29. | 2012 | HIV | Faruk Sinangil |
| Francis | Deadly AIDS policy failure by the highest levels of the US government: a personal look back 30 years later for lessons to respond better to future epidemics. | Journal of Public Health Policy (2012) 33, 290–300. doi:10.1057/jphp.2012.14 | 2012 | HIV | Don Francis |
| Francis | Protecting the public’s health: remove the political constraints that hamper the Centers for Disease Control and Prevention. | AIDS. 2012 Jun 1;26(9):1175-6. doi:10.1097/QAD.0b013e32835392dd | 2012 | General | Don Francis |
| Karasavvas et al | The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120 | AIDS Research and Human Retroviruses. November 2012, 28(11): 1444-1457. doi: 10.1089/aid.2012.0103 | 2012 | HIV | Faruk Sinangil |
| Mahoney et al | Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil. | Vaccine, Volume 30, Issue 32, 6 July 2012, Pages 4892-4896, ISSN 0264-410X, 10.1016/j.vaccine.2012.02.064. | 2012 | Dengue | Don Francis |
| Montefiori et al | Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. | J Infect Dis. (2012) 206(3): 431-441. doi:10.1093/infdis/jis367 | 2012 | HIV | Don Francis, Carter Lee, and Faruk Sinangil |
| O'Rourke et al | Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies. | J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29. | 2012 | HIV | Faruk Sinangil |
| Rerks-Ngarm et al | Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. | J Infect Dis. first published online July 26, 2012 doi:10.1093/infdis/jis478 | 2012 | HIV | Don Francis |
| Robb et al | Risk behavior and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. | The Lancet Infectious Diseases, Volume 12, Issue 7, Pages 531 - 537, July 2012. DOI: 10.1016/S1473-3099(12)70088-9 | 2012 | HIV | Don Francis |
| Alam et al | Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen is Enhanced by a gp120 N-terminal Deletion | J. Virol. February 2013 87:3 1554-1568; published ahead of print 21 November 2012, doi:10.1128/JVI.00718-12 | 2012 | HIV | Faruk Sinangil |
| Stephenson et al | Preexisting Adenovirus Seropositivity Is Not Associated With Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials. | J Infect Dis. (2012) 205(12): 1806-1810 first published online April 5, 2012 doi:10.1093/infdis/jis285 | 2012 | HIV | Faruk Sinangil |
| Arita et al | Safe landing for global polio eradication: A Perspective. | Vaccine. 29 (2011) 8827-34. doi:10.1016/j.vaccine.2011.09.059 | 2011 | Polio | Don Francis |
| Barouch et al | International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. | Vaccine. 2011 Jul 18;29 (32):5203-9. Epub 2011 May 25. doi:10.1016/j.vaccine.2011.05.025 | 2011 | HIV | Faruk Sinangil |
| Bonsignori et al | Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. | J Virol. 2011 Oct;85(19):9998-10009. Epub 2011 Jul 27. doi:10.1128/JVI.05045-11 | 2011 | HIV | Faruk Sinangil |
| Francis et al | WHO Influenza vaccine technology transfer initiative: Role and activities of the Technical Advisory Group. | Vaccine 295 (2011) A45-A47. doi:10.1016/j.vaccine.2011.02.078 | 2011 | Influenza | Don Francis |
| Mahoney et al | Dengue vaccines regulatory pathways: A report on two meetings with regulators of developing countries. | PLoS Med 8(2): e1000418. Published February 22, 2011. doi:10.1371/journal.pmed.1000418. | 2011 | Dengue | Don Francis |
| Bonsignori et al | Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. | J Virol. 2011 Oct;85(19):9998-10009. doi: 10.1128/JVI.05045-11. Epub 2011 Jul 27. | 2011 | HIV | Faruk Sinangil |
| Barouch et al | International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. | Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25. | 2011 | HIV | Faruk Sinangil |
| Perez-Losada et al | Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand. | PLoS One. 2011 Mar 10;6(3):e16902. doi:10.1371/journal.pone.0016902 | 2011 | HIV | Faruk Sinangil |
| Pitisuttihum et al | Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. | PLoS Vol 6, Issue 12, e27837, December 2011. doi:10.1371/journal.pone.0027837 | 2011 | HIV | Don Francis |
| MOPH-TAVEG | Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). | Vaccine 29 (2011) 4285-4292. doi:10.1016/j.vaccine.2011.03.014 | 2011 | HIV | Don Francis |
| Francis | Successes and failures: Worldwide vaccine development and application. | Biologicals. 2010 Sep;38(5):523-8. Epub 2010 Aug 4. Review. doi:10.1016/j.biologicals.2010.06.003 | 2010 | General | Don Francis |
| Francis et al | The manufacture and supply of dengue vaccine. | Occasional Paper, Pediatric Dengue Vaccine Initiative, International Vaccine Institute, December 2010. | 2010 | Dengue | Don Francis |
| Gilbert et al | Magnitude and breadth of a non-protective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. | J Infect Dis 202 (4): 595-605 (2010). doi: 10.1086/654816 | 2010 | HIV | Faruk Sinangil |
| O'Rourke et al | Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. | J Virol. 2010 Nov;84(21):11200-9. doi:10.1128/JVI.00790-10 | 2010 | HIV | Faruk Sinangil |
| Perez-Losada et al | Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America. | Mol Biol Evol 27(2):417-25 (2010). doi: 10.1093/molbev/msp254 | 2010 | HIV | Faruk Sinangil |
| Smith et al | Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. | PLoS One 5(8): e12076 (2010). Doi:1371/journal.pone.0012076 | 2010 | HIV | Faruk Sinangil |
| O'Rourke et al | Novel ring structure in the gp41 trimer of human deficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. | J Virol. 83(15):7728-38 (2009). doi:10.1128/JVI.00688-09 | 2009 | HIV | Faruk Sinangil |
| Perez-Losada et al | Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. | Retrovirology 6:67 (2009). doi:10.1186/1742-4690-6-67 | 2009 | HIV | Faruk Sinangil |
| Rerks-Ngarm et al | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. | N Engl J Med. 2009 Dec 3;361(23):2209-20. Epub 2009 Oct 20. doi:10.1056/NEJMoa0908492 | 2009 | HIV | Don Francis |
| Pitisuttihum et al | Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. | J Med Assoc Thai. 2007 Nov;90(11):2442-8. | 2007 | HIV | Don Francis |
| Jobes et al | High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV-1 infections from a Phase 3 vaccine efficacy trial. | AIDS Res Hum Retroviruses 22 (10):1014-21 (2006). doi:10.1089/aid.2006.22.1014 | 2006 | HIV | Faruk Sinangil |
| Jobes et al | Longitudinal population analysis of dual infection with recombination in two strains of HIV-1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial. | AIDS Res Hum Retroviruses 22 (10): 968-78 (2006). doi: 10.1089/aid.2006.22.968 | 2006 | HIV | Faruk Sinangil |
| © 2006-2022 Global Solutions for Infectious Diseases, All Rights Reserved |